growth
Conditions
Interventions
dietary supplement iKids-Growth for children treatment group:None
Non-iKids-Growth treatment group:none
Sponsors
Affiliated Hospital of North Sichuan Medica College
Eligibility
Sex/Gender
All
Age
5 Years to 11 Years
Inclusion criteria
Inclusion criteria: 1. Girls aged 5-10 years old (i.e., the actual age of girls must be 5 years old and above, under 11 years old, excluding 11 years old) and bone age = 11.5 years old, boys aged 5-11 years old (i.e., boys must be 5 years old and above, under 12 years old, excluding 12 years old) and bone age P3 and <= P25; 3. predict lifetime height <genetic target height*, or predict lifetime height corresponding to the 18-year-old height percentile of the same gender <P10 (i.e., predicted lifetime height < 164.9cm for boys and 153.7cm for girl<s); 4. Participants only took the children's dietary supplement iKids-Growth for height improvement during the study, and did not receive other hormone therapy (such as growth hormone, sex hormones, glucocorticoids, etc.) and drug therapy that interfered with growth hormone secretion or growth hormone effects (such as xandrolone, growth hormone-releasing hormone, etc.); 5. Participants and/or guardians understand the purpose of the study, the possible risks and benefits of the study, agree to participate in this clinical study, and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with abnormal blood glucose and lipid levels (fasting blood glucose >= 5.6mmol/L); 2.The difference between bone age and actual age is greater than 1 year; 3.Liver and kidney dysfunction (ALT>1.5 times the upper limit of normal, Cr>upper limit of normal); 4.There are thyroid function-related diseases; 5.Diagnosed with growth hormone deficiency (GHD), idiopathic short status (ISS), Turner syndrome, Prader Willi syndrome, Noonan syndrome; 6.Diagnosed with other growth and development related diseases; 7.Individuals who have received systemic or local hormone therapy (such as growth hormone, sex hormone, glucocorticoid, etc.) within 3 months, as well as those who have received medication therapy that may interfere with GH secretion or GH action (such as oxyandrolone, growth hormone releasing hormone, etc.); 8.Height percentile for corresponding age <= P3; 9.History of severe congenital heart disease, asthma, chronic liver disease, kidney disease and other systemic diseases; 10.Participants with a history of severe allergies or allergies to the dietary supplements used in this clinical study; 11.Participated in drug clinical research within 3 months; 12.Guardians with cognitive impairments; 13.Researchers believe that other situations are not suitable for inclusion in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| gowth; | — |
Secondary
| Measure | Time frame |
|---|---|
| weight;fasting blood sugar;total bilirubin;direct bilirubin;indirect bilirubin;Alanine aminotransferase;Aspartaminotransferase;serum creatinine;serum urea;FSH,Follicle-stimulating hormone;luteinizing hormone;estradiol;progesterone;androstenedione;prolactin; | — |
Countries
China
Contacts
Public ContactCheng Wang
Affiliated Hospital of North Sichuan Medica College
Outcome results
None listed